Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)

Appears undervalued based on drugs approved in the pipeline. Also is a potential take over cadidiate

Eoquin first and foremost is going to bring in $500M a year starting in 2013.

On top of that you have F and Z picking up significant steam and B, which looks to have positive results from it's trial.

Not to mention many other drugs in the pipeline.

Zevalin is the key

2 profitable FDA approved drugs already. 2 pipeline drugs set for approval by 2013. 4 more in the pipeline behind them. Plus one of the best CEO's in the industry.

pharma
no div
Total Debt / Equity    0.00
Price Earnings    17.90
Price/Sales    4.62
Price/Book    4.62
Price/Cash Flow    20.90

50 All-Stars, 6 Wall Streeters...I'm in.

Results consistently above expectations and great positioning in the market. Pop above previous high for technical pattern caught major market attention.

Undervalued--Belinostat and Apaziquone have the potential to be huge and the Fusilev shortage isn't going away. Zevalin also can be a blockbuster with the removal of the bioscan in November.

might be a good company but overvalued at present time. all speculation

$17 by end of year.

Even if not taken over by Big Pharma, this is one worth paying attention to.

While the company is spending large amounts on R&D, they are also increasing sales every year.

takeover target

record sales and profits this quarter, nice pipeline, looks like a promising takeover target, what more could you ask for in a speculative bio tech

good company with potential to explode when FDA approves

Great pipeline of drugs, positive momentum right now, recent guidance to continue the belinostat study and pending FDA approval for Fusilev use with chemotherapy in late April

This stock is under valued and is certainly not going down. There is too much positive publicity and their management is too good to cause a drop in price.

It is inevitable, this is a strong pick.

Perhaps the FDA will approve Fusilev for mCRC on or before April 29, 2011.

With FDA approval and full reimbursement, it is believed that many doctors will gravitate towards Fusilev. Here's why:

Reliability - Fusilev supplies should be sufficient to meet future demands (excluding the ongoing, short-term Cangene plant closing).

Ready-to-Use - SPPI recently submitted a second sNDA for a Ready-to-Use version of Fusilev that will make it more convenient for end-users to administer the treatment to patients. That's good stuff.

Less Toxicity - Fusilev has been shown in some studies to be less toxic than its generic competitor. With annual sales of $200 million in the EU, it certainly appears that doctors overseas prefer the potentially less toxic levoleucovorin (Fusilev) over the generic.

REVENUE GROWTH
Post FDA approval, Fusilev has $8 to $10 million / quarter potential. Coupled with continued growth of Zevalin sales, SPPI could generate $100 million+ in total revenue during FY 2011.